Brain HealthGLP-1 Drugs Failed in Alzheimer's Trials but May Still Protect Cognition Earlier
GLP-1 drugs such as semaglutide (Ozempic) and tirzepatide (Mounjaro) may affect the brain as well as weight and blood sugar. Researchers from the University of Gothenburg and University of Copenhagen reviewed the evidence for the journal Science. Animal studies suggest these drugs can influence learning and memory, but human data are less consistent. Health-record studies link GLP-1 treatment to lower dementia risk in type 2 diabetes, though these associations cannot prove cause. Importantly, Novo Nordisk's EVOKE and EVOKE+ trials found semaglutide did not slow early Alzheimer's disease, even though some Alzheimer's-related biomarkers shifted. The authors suggest the drugs may work better for people with obesity or diabetes who have attention, planning and processing-speed problems tied to metabolic and vascular health, especially if treatment starts before cognitive decline. Whether benefits come from metabolic improvement, direct brain action, or both remains unknown.